Technical Data
T8180-15B
TRAIL, Recombinant, Human (TNF-Related Apoptosis Inducing Ligand, Apo2L, TL2, TNFSF10)
50ug
250ug
250ug
|
Technical Data |
|
T8180-15B |
TRAIL, Recombinant, Human (TNF-Related Apoptosis Inducing Ligand, Apo2L, TL2, TNFSF10) |
50ug 250ug |
| Growth Factors, Cytokines | Storage: -70°CShipping: Dry Ice |
|
TRAIL, 114-281 aa, Human, Recombinant, E. coli Recombinant human TRAIL was expressed in E.coli and purified by using conventional chromatography techniques. TNF-related apoptosis-inducing ligand (TRAIL) belongs to the tumor necrosis factor (TNF) cytokine family and induces rapid apoptosis in a wide variety of tumor cell lines upon binding to the death-signalling receptors on the cell membrane. TRAIL binds to one of four receptors that have been identified in humans, including TRAIL-R1/DR4, TRAIL-R2/KILLER/DR5, TRAIL-R3/DcR1/TRID, and TRAIL-R4/DcR2/TRUNDD. Both DR4 and DR5 are pro-apoptotic receptors, which contain a cytoplasmic death domain and mediate apoptosis on binding to TRAIL. By contrast, TRID and TRUNDD do not contain a cytoplasmic death domain and block the function of TRAIL by competing with DR4 and DR5 for binding of TRAIL. Molecular Weight: 23kD (211 aa) Amino Acid Sequence: MVRERGPQRV AAHITGTRGR SNTLSSPNSK NEKALGRKIN SWESSRSGHS FLSNLHLRNG ELVIHEKGFY YIYSQTYFRF QEEIKENTKN DKQMVQYIYK YTSYPDPILL MKSARNSCWS KDAEYGLYSI YQGGIFELKE NDRIFVSVTN EHLIDMDHEA SFFGAFLVG Storage and Stability: May be stored at 4°C for short-term only. For long-term storage, aliquot to avoid repeated freezing and thawing and freeze at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months. Molecular Weight: 23kD (211 aa) |
Source: Human, Recombinant, E. coli Purity: 95% by SDS-PAGE Concentration: ~1mg/ml Form: Supplied as a liquid in 20mM Tris pH 7.5, 300mM NaCl, 0.1mM DTT, 10% glycerol. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
|
1. Human Brain Astrocytes Mediate TRAIL-mediated Apoptosis after Treatment with IFN-gamma. Yonsei Med J 2006 Jun 30;47(3):354-8 2. [Influence of Chemotherapy on Expression of TRAIL in Primary Acute Leukemic Cells.] Zhongguo Shi Yan Xue Ye Xue Za Zhi 2006 Jun;14(3):481-4 3. Improvement of Expression Level and Bioactivity of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Novel Zinc ion Feeding Strategy Lett 2006 Jun 24; 4. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006 Jun 23; 5. TRAIL-induced apoptosis proceeding from caspase-3-dependent and -independent pathways in distinct HeLa cells. Biochem Biophys Res Commun 2006 Jun 12; 6. [Effects of hTERT RNAi on apoptosis of hepatocellular carcinoma cells induced by TRAIL.] Zhonghua Gan Zang Bing Za Zhi 2006 Jun;14(6):435-40 7. Janssen EM, et al , (2005). Nature. Mar 3;434(7029):88-93 8. Nagane M , et al , (2001). Apoptosis. Jun;6(3):191-7.
|
||